Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company focused on oncology, announced the grant of stock options to six new employees on October 15, 2021. A total of 177,000 shares were offered at an exercise price of $5.14, matching the closing price on the grant date. The options are part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020. CytomX specializes in conditionally activated therapeutics, employing its Probody® technology platform, to target cancer with minimized toxicity.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Alan Ashworth, Ph.D., a distinguished cancer researcher, to its board of directors. Dr. Ashworth, known for identifying the BRCA2 gene and developing PARP inhibitors, brings extensive experience to advance CytomX's clinical pipeline. President Sean McCarthy emphasized Dr. Ashworth's expertise in translational sciences will be valuable as the company targets key Phase 2 milestones. CytomX focuses on conditionally activated therapeutics using its Probody technology to improve cancer treatment outcomes while minimizing toxicity.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced the granting of stock options to nine new employees, totaling 157,200 shares at an exercise price of $4.97, matching the closing price on September 15, 2021. These options were issued under the 2019 Employment Inducement Incentive Plan to attract new talent. CytomX is focused on developing conditionally activated therapeutics for cancer treatment based on its Probody technology, with significant collaborations with major firms like AbbVie and Bristol Myers Squibb, and a portfolio featuring multiple candidates in clinical trials.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., will participate in a virtual fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.
The pre-recorded session will be available for on-demand viewing starting September 13 at 7:00 a.m. ET on CytomX’s website, with a 90-day archive afterwards. CytomX is developing Probody therapeutics aimed at treating cancer, focusing on minimizing toxicity while enhancing treatment efficacy.
CytomX Therapeutics (CTMX) announced the grant of stock options to seven new employees for a total of 172,600 shares at $4.81 each, reflecting the closing price on August 16, 2021. This grant, made under the 2019 Employment Inducement Incentive Plan, aims to attract new talent. CytomX, an oncology-focused biopharmaceutical firm, specializes in conditionally activated antibody therapeutics using its Probody® technology platform to target cancer effectively while minimizing toxicity. The company collaborates with major pharmaceutical partners and has a clinical pipeline advancing towards Phase 2 studies.
CytomX Therapeutics (CTMX) reported its Q2 2021 financial results, showing $16 million in revenue, consistent with Q2 2020. Cash reserves totaled $366 million, up from $316 million at year-end 2020. The company continues to advance its Probody therapeutics pipeline with ongoing Phase 2 studies for leading drug candidates CX-2009 and CX-2029. Initial data from CX-2009, impacted by COVID-19, is now expected in 2022, while data from CX-2029 is anticipated in Q4 2021. Five peer-reviewed publications in 2021 highlight CytomX's scientific advancements.
CytomX Therapeutics (Nasdaq: CTMX) announced significant findings related to its investigational drug pacmilimab (CX-072) in three peer-reviewed publications. Pacmilimab exhibited single-agent activity in advanced solid tumors, notably in metastatic triple-negative breast cancer (TNBC). It demonstrated potential for combination therapies with ipilimumab, addressing limitations of conventional immune checkpoint inhibitors. The overall objective response rate (ORR) in patients treated was 12%, with a disease control rate of 42%. Results suggest pacmilimab may provide a safer alternative with reduced toxicity.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two upcoming virtual investor conferences. The BTIG 5th Virtual Biotechnology Conference is scheduled for August 9, 2021, at 1:00 p.m. ET, followed by the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, with a panel discussion at 1:10 p.m. ET. CytomX focuses on developing Probody therapeutics, which are designed to selectively target tumors and minimize toxicity. The company collaborates with leaders in the biotechnology sector and has a robust clinical pipeline.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming release of its second quarter 2021 financial results on August 5, 2021, after U.S. market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide updates on corporate developments. CytomX focuses on developing conditionally activated therapeutics utilizing its Probody® technology platform, aimed at enhancing cancer treatment efficacy while minimizing toxicity. The company collaborates with prominent firms like AbbVie and Bristol Myers Squibb on various clinical-stage assets.
CytomX Therapeutics reported positive results from the Phase 1 study of CX-2029, the first CD71-targeting antibody-drug conjugate (ADC), highlighting its well-tolerated safety profile.
The study, published in Clinical Cancer Research, involved 45 patients with advanced solid tumors, showing encouraging anti-tumor responses at doses of 2 mg/kg and higher.
The recommended Phase 2 dose is 3 mg/kg every three weeks. The ongoing Phase 2 expansion study targets various cancers, with initial results expected in Q4 2021.